

Table 2. US Food and Drug Administration–Approved Biologic and Oral Systemic Treatments for Psoriasis

Systemic treatment	Structure of biologic or target of oral systemic	Dosing for plaque psoriasis ^a	Efficacy at primary end point ^b	Safety considerations
Biologics				
Anti-IL-17				
Secukinumab	Human monoclonal IL-17A antibody	<p>Loading/induction dose: 300 mg at weeks 0, 1, 2, 3, and 4</p> <p>Maintenance dose: 300 mg every 4 weeks</p> <p>Recommended escalated maintenance dose: 300 mg every 2 weeks</p>	<p>Adults: 82% achieve PASI 75 at week 12 (placebo: 4%); 65% achieve IGA 0/1 at week 12 (placebo, 2%)⁶⁹</p> <p>Superior to etanercept and ustekinumab at 1 year^{69,70}</p> <p>High efficacy for scalp, nail, and palmoplantar psoriasis⁷¹⁻⁷³</p>	<p>Avoid use in patients with a history of inflammatory bowel disease</p> <p>Low rates of mild mucocutaneous candidiasis</p> <p>Discontinue during serious infection until the infection resolves</p>
Ixekizumab	Humanized monoclonal IL-17A antibody	<p>Loading/induction dose: 160 mg at week 0; 80 mg at weeks 2, 4, 6, 8, 10, and 12</p> <p>Maintenance dose: 80 mg every 4 weeks</p> <p>Recommended escalated maintenance dose: 80 mg every 2 weeks</p>	<p>Adults: 90% achieve PASI 75 at week 12 (placebo, 2%); 83% achieve IGA 0/1 at week 12 (placebo, 2%)⁶⁰</p> <p>Superior to etanercept at 12 weeks, ustekinumab at 1 year, and adalimumab at 24 weeks^{60,74,75}</p>	<p>Avoid use in patients with a history of inflammatory bowel disease</p> <p>Low rates of mild mucocutaneous candidiasis</p> <p>Discontinue during serious infection until the infection resolves</p>
Brodalumab	Human monoclonal IL-17A receptor antibody	<p>Loading/induction dose: 210 mg at weeks 0, 1, and 2</p> <p>Maintenance dose: 210 mg every 2 weeks</p> <p>Recommended escalated maintenance dose: 40 mg once weekly</p>	<p>Adults: 86% achieve PASI 75 at week 12 (placebo, 8%); 80% achieve IGA 0/1 at week 12 (placebo, 4%)⁷⁶</p> <p>Superior to ustekinumab at 12 weeks⁷⁶</p>	<p>Avoid use in patients with a history of inflammatory bowel disease</p> <p>Low rates of mild mucocutaneous candidiasis</p> <p>Discontinue during serious infection until the infection resolves</p> <p>Weigh benefit and risks in patients with a history of suicidal ideation or behavior</p>